References
- 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
- 2. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380: 1840-50.
- 3. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-7.
- 4. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-74.
- 5. Ariga H, Nemoto K, Miyazaki S, Yoshioka T, Ogawa Y, Sakayauchi T, et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009; 75: 348-56.
- 6. Nishimura Y, Mitsumori M, Hiraoka M, Koike R, Nakamatsu K, Kawamura M, et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother Oncol 2009; 92: 260-5.
- 7. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-702.
- 8. Uno T, Isobe K, Kawakami H, Ueno N, Kobayashi H, Shimada H, et al. Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer. Anticancer Res 2004; 24: 2483-6.
- 9. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, et al. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 2009; 74: 482-9.
- 10. Kawashima M, Kagami Y, Toita T, Uno T, Sugiyama M, Tamura Y, et al. Prospective trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys 2006; 64: 1112-21.
- 11. Isacsson U, Lennernäs B, Grusell E, Jung B, Montelius A, Glimelius B. Comparative treatment planning between proton and x-ray therapy in esophageal cancer. Int J Radiat Oncol Biol Phys 1998; 41: 441-50.
- 12. Zhang X, Zhao KL, Guerrero TM, McGuire SE, Yaremko B, Komaki R, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2008; 72: 278-87.
- 13. Pan X, Zhang X, Li Y, Mohan R, Liao Z. Impact of using different four-dimensional computed tomography data sets to design proton treatment plans for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2009; 73: 601-9.
- 14. Sugahara S, Tokuuye K, Okumura T, Nakahara A, Saida Y, Kagei K, et al. Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys 2005; 61: 76-84.
- 15. Mizumoto M, Sugahara S, Nakayama H, Hashii H, Nakahara A, Terashima H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol 2010; 186: 482-8.
- 16. Shohei K, Hirohiko T. Proton Beam Therapy with High-Dose Irradiation for Superficial and Advanced Esophageal Carcinomas. Clin Cancer Res 2003; 9: 3571-7.
- 17. Mizumoto M, Sugahara S, Okumura T, Hashimoto T, Oshiro Y, Fukumitsu N, et al. Hyperfractionated concomitant boost proton beam therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: e601-6.
- 18. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 83: e345-51.
- 19. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009; Revised Version 4.03 June 14, 2010. U. S. Department of Health and Human Sevices [citated 2015 Mar 14]. Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
- 20. Nemoto K, Matsumoto Y, Yamakawa M, Jo S, Ito Y, Oguchi M, et al. Treatment of superficial esophageal cancer by external radiation therapy alone: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys 2000; 46: 921-5.
- 21. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol 2011; 6: 115-20.
- 22. Liu M, Shi X, Guo X, Yao W, Liu Y, Zhao K, et al. Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial. Radiat Oncol 2012; 7: 142.
- 23. Zhao KL, Ma JB, Liu G, Wu KL, Shi XH, Jiang GL. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys 2010; 76: 446-51.
- 24. Kawaguchi Y, Nishiyama K, Miyagi K, Suzuki O, Ito Y, Nakamura S. Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 2011; 41: 1007-12.
- 25. Ji K, Zhao L, Yang C, Meng M, Wang P. Three-dimensional conformal radiation for esophageal squamous cell carcinoma with involved-field irradiation may deliver considerable doses of incidental nodal irradiation. Radiat Oncol 2012; 7: 200.
- 26. Zhang X, Li M, Meng X, Kong L, Zhang Y, Wei G, et al. Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2014; 9: 64.